MedTrace Logo

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

NCT03100942 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2020-10-23

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to assess the efficacy of filgotinib, lanraplenib, and tirabrutinib in adults with active Sjogren's Syndrome (SjS).

Conditions

  • Sjogren's Syndrome

Interventions

DRUG

Lanraplenib

1 x 30 mg tablet administered orally once daily

DRUG

Filgotinib

1 x 200 mg tablet administered orally once daily

DRUG

Tirabrutinib

1 x 40 mg tablet administered orally once daily

DRUG

Lanraplenib placebo

1 x tablet administered orally once daily

DRUG

Filgotinib placebo

1 x tablet administered orally once daily

DRUG

Tirabrutinib placebo

1 x tablet administered orally once daily

Sponsors & Collaborators

  • Galapagos NV

    collaborator INDUSTRY

  • Ono Pharmaceutical Co. Ltd

    collaborator INDUSTRY

  • Gilead Sciences

    lead INDUSTRY

Principal Investigators

  • Gilead Study Director · Gilead Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2019-01-10
Completion
2019-10-02
FDA Drug
Yes

Countries

  • United States
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03100942 on ClinicalTrials.gov